5 Monster Stocks to Hold for the Next 10 Years These companies are just starting to realize the potential in up-and-coming fields, like AI and gene editing.
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.
3 Monster Stocks to Hold for the Next 10 Years The planets are lining up for these three stocks' underlying companies.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs.
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought The iconic growth investor made some interesting moves during Friday's market pullback.
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.
